Related Experiment Video

Updated: Apr 1, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Hepatoma targeting peptide conjugated bio-reducible polymer complexed with oncolytic adenovirus for cancer gene

Joung-Woo Choi1, Hyun Ah Kim1, Kihoon Nam1

  • 1Center for Controlled Chemical Delivery (CCCD), Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|October 6, 2015
PubMed

Insights

This study developed a novel polymer-adenovirus (Ad) vector system for targeted liver cancer gene therapy. The new system enhances Ad delivery to cancer cells, reduces immune response, and improves therapeutic efficacy against hepatoma.

Area of Science:

  • Oncolytic virotherapy
  • Gene therapy
  • Nanomedicine

Background:

  • Adenovirus (Ad) vectors are promising for cancer gene therapy but face challenges in tumor targeting and immune response.
  • Hepatoma (liver cancer) requires targeted delivery systems to improve therapeutic outcomes.

Purpose of the Study:

  • To develop a tumor-targeting bioreducible polymer conjugated with adenovirus for enhanced hepatoma treatment.
  • To evaluate the specificity, safety, and efficacy of the novel vector system in preclinical models.

Main Methods:

  • Construction of an arginine-grafted bioreducible polymer (ABP)-PEG-HCBP1 conjugated with adenovirus.
  • Assessment of hepatoma cell uptake, transduction efficiency, and immune response modulation.
  • Evaluation of oncolytic adenovirus (oAd) delivery and cancer cell killing efficacy in vitro and in vivo.

Main Results:

  • The HCBP1-conjugated Ad vector demonstrated hepatoma-specific uptake and transduction.
  • The polymer conjugate protected Ad from serum and reduced innate and adaptive immune responses.
  • The oAd/polymer complex significantly enhanced cancer cell killing and reduced Met and VEGF expression in hepatoma cells.

Conclusions:

  • HCBP1-conjugated bioreducible polymers can serve as effective carriers for oncolytic adenovirus delivery.
  • This strategy offers a promising approach for safe and efficient hepatoma gene therapy.
Keywords:
Active targetingBioreducible polymerCancer gene therapyHepatoma cancer targeting peptideOncolytic adenovirus

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

13.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
109
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
28.1K